The Gentris Mission
Gentris Corporation is a global provider of pharmacogenomic testing and biorepository services. As pioneers in the field, Gentris helps pharmaceutical companies and clinical research organizations effectively integrate pharmacogenomics into their drug development programs to deliver safer, more effective compounds to the market more quickly. With better characterization of patient populations, pharmacogenomics can help reduce drug failure rates by enabling drug companies to modify patients’ exposure to drugs based on their genomic drug-response profile. This ensures that the right drugs reach the right patients at the right doses, and provides optimal benefits for their pharmacogenomic profile.
Strategic partnerships have been created with top scientists to lead collaborative, cutting-edge research projects, provide scientific education and training, and advise clients on the application of genomic biomarkers for drug development. The first of these partnerships was established with Dr. Howard McLeod, Fred Eshelman Distinguished Professor and Director of the Institute for Pharmacogenomics and Individualized Therapy at The University of North Carolina at Chapel Hill, and Founder of the non-profit organization Pharmacogenomics for Every Nation Initiative (PGENI). Dr. McLeod now serves as Gentris’ Chief Scientific Advisor, where he helps guide the scientific direction of the company. As a result of this collaboration, joint projects are underway and may lead to new pharmacogenomics solutions that will spur the next generation of personalized medicines.
Gentris Portfolio of Services
Quality, expertise, and customer satisfaction drive Gentris’ core business model. We provide seamless and dynamic coupling of comprehensive project life cycle management and full logistics support with the power of tested platforms for sample extraction and purification, genotyping, gene expression analysis, and highly customized pharmacogenomics (PGx) solutions.
Innovative Biomarker Solutions